
Lirafugratinib + LITESPARK011
8 snips
Oct 1, 2026 Lirafugratinib’s approval brings a fresh look at FGFR inhibitors for FGFR2-altered cholangiocarcinoma, including phosphate, eye, skin, and drug-interaction concerns. The discussion then turns to LITESPARK-011, comparing lenvatinib plus belzutifan with cabozantinib in advanced clear-cell kidney cancer, with attention to response rates, toxicity, quality of life, and still-immature survival data.
AI Snips
Chapters
Transcript
Episode notes
Lirafugratinib Targets A Defined Cholangiocarcinoma Subgroup
- Lirafugratinib targets FGFR2 more selectively than other inhibitors and treats FGFR2-fusion or rearrangement cholangiocarcinoma.
- These alterations occur in roughly 10–15% of intrahepatic cholangiocarcinomas, making biomarker testing essential.
FGFR2 Selectivity Trades Phosphate For Eye Toxicity
- FGFR2 selectivity may reduce hyperphosphatemia while increasing ocular toxicity compared with broader FGFR inhibitors.
- Lirafugratinib caused hyperphosphatemia in 21% but retinal pigment epithelial detachment or related retinopathy in 31%.
Check Interactions And Interpret Creatinine Carefully
- Review interacting medications carefully before starting lirafugratinib because it is a CYP3A4 substrate and inhibits numerous transporters.
- Consider cystatin C when creatinine rises, since OCT2 and MATE1 inhibition may increase creatinine without true renal dysfunction.
